EULAR updates guidance on immunomodulators for severe COVID-19

Experts have outlined the most current treatment strategies for immunomodulators in moderate-to-severe and critical COVID-19, updating 12 EULAR ‘points to consider’ on their therapeutic use with the most recent clinical data. Following a literature review, a multidisciplinary task force including Dr Pedro Machado, a consultant rheumatologist at University College Hospital, concluded that tocilizumab in combination ...

Already a member?

Login to keep reading.

© 2021 the limbic